Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2023-09-12 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
2023年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the "2023 third extraordinary general meeting of shareholders" of Xintiandi Pharmaceutical Co., Ltd. It details the meeting date, voting procedures, attendance, and the voting results on specific proposals such as the election of a director and change of accounting firm. It also includes legal opinions confirming the legality of the meeting and voting process. The document is a formal announcement of the voting results from a shareholders' meeting, not the meeting materials or the meeting itself. The document length is relatively short (2678 characters), and it focuses on the voting outcomes rather than detailed financial or management reports. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-09-12 Chinese
北京市天元律师事务所关于新天地药业股份有限公司2023年第三次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, attendance, and voting procedures of the 2023 third extraordinary shareholders' meeting of a company. It details the meeting date, voting results, and compliance with laws and company articles. It does not contain financial statements or management discussion but focuses on the legality and validity of the shareholders' meeting and its resolutions. This type of document corresponds to the Declaration of Voting Results & Voting Rights Announcements category, as it officially reports the voting outcomes of a shareholders' meeting.
2023-09-12 Chinese
第五届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fifteenth meeting of the fifth board of directors of the company 新天地药业股份有限公司. It includes details about the meeting date, attendance, and the approval of a donation proposal. There is no financial data, no detailed report, or presentation content. The document is an official announcement of board decisions, specifically about a corporate governance matter (approval of donation). This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length is short and it is not a report or financial statement, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing (RNS) because it is a specific board meeting resolution announcement. Therefore, the best classification is MANG with high confidence.
2023-09-06 Chinese
关于对外捐赠额度的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the approval of an external donation amount by the board of directors. It includes details about the board meeting, the donation amount, and compliance with stock exchange listing rules. The document is short (715 characters) and does not contain financial statements or detailed financial data. It is an announcement of a corporate action related to social responsibility, not a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is also not a management change, voting result, or capital change. The best fitting category is Regulatory Filings (RNS), which covers miscellaneous corporate announcements that do not fit other specific categories.
2023-09-06 Chinese
关于变更会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the company's auditor (accounting firm) from KPMG Huazhen to Grant Thornton for the 2023 fiscal year. It details the reasons for the change, qualifications of the new auditor, communication with the previous auditor, and approvals from the audit committee, board of directors, and independent directors. It also mentions that the appointment is subject to shareholder approval at an upcoming extraordinary general meeting. The document does not contain any financial statements, audit reports, or detailed financial data itself, but rather is a formal announcement about the auditor change and related governance procedures. The document length is 3560 characters, which is relatively short and consistent with an announcement rather than a full audit report or annual report. Therefore, this filing is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about auditor change and does not contain the audit report itself or detailed financial data.
2023-08-24 Chinese
2023年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "新天地药业股份有限公司2023 年半年度财务报告" which translates to "Xintiandi Pharmaceutical Co., Ltd. 2023 Half-Year Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2023. The report explicitly states it is a half-year report and includes unaudited financial data. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or certification. Therefore, the correct classification is IR. H1 2023
2023-08-24 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.